Given that IL-6 shares an important pathogenetic role in AOSD, as mentioned above, the interleukin-6 (IL-6) antagonist, tocilizumab (TOC), has recently been proposed as a potential treatment for these patients. Here, IL6 is linked to adult-onset Still disease.